Evidence
Med Sci Monit. 2024 Jan 29;30:e943417. doi: 10.12659/MSM.943417.
ABSTRACT
Metabolic dysfunction-associated fatty liver disease or metabolic dysfunction-associated steatotic liver disease (MAFLD/MASLD), is a common chronic liver condition affecting a substantial global population. Beyond its primary impact on liver function, MAFLD/MASLD is associated with a myriad of extrahepatic manifestations, including cognitive impairment. The scope of cognitive impairment within the realm of MAFLD/MASLD is a matter of escalating concern. Positioned as an intermediate stage between the normal aging process and the onset of dementia, cognitive impairment manifests as a substantial challenge associated with this liver condition. Insights from studies underscore the presence of compromised executive function and a global decline in cognitive capabilities among individuals identified as being at risk of progressing to liver fibrosis. Importantly, this cognitive impairment transcends mere association with metabolic factors, delving deep into the intricate pathophysiology characterizing MAFLD/MASLD. The multifaceted nature of cognitive impairment in the context of MAFLD/MASLD is underlined by a spectrum of factors, prominently featuring insulin resistance, lipotoxicity, and systemic inflammation as pivotal contributors. These factors interplay within the intricate landscape of MAFLD/MASLD, fostering a nuanced understanding of the links between hepatic health and cognitive function. By synthesizing the available evidence, exploring potential mechanisms, and assessing clinical implications, the overarching aim of this review is to contribute to a more complete understanding of the impact of MAFLD/MASLD on cognitive function.
PMID:38282346 | DOI:10.12659/MSM.943417
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
🌐 90 Days
VR Related Evidence Matrix
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Liver Disease (MASLD): Another matter to face through a holistic approach
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Liver Disease (MASLD): Another matter to face through a holistic approach
- Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Spatial genomics: mapping human steatotic liver disease
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
- The Global Epidemic of Metabolic Fatty Liver Disease
- Inflammatory liver diseases and susceptibility to sepsis
- Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease
- Metabolic Muddle. MASLD and MASH on the Horizon
- White Adipose Tissue in Metabolic Associated Fatty Liver Disease
- Healthy Lifestyle and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Large Prospective Cohort Study
- Electrocardiographic Abnormalities in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
- Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity
- The relationship between advanced liver fibrosis and osteoporosis in type 2 diabetes patients with MAFLD
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
- Energy Metabolism in Residents in the Low- and Moderate Altitude Regions of Central Asia with MAFLD and Type 2 Diabetes Mellitus
- COVID-19 in Individuals with Chronic Liver Diseases
- Correlation of alanine aminotransferase levels and a histological diagnosis of steatohepatitis with ultrasound-diagnosed metabolic-associated fatty liver disease in patients from a centre in Nigeria
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort
- Imbalance of mitochondrial fusion in peripheral blood mononuclear cells is associated with liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis
- Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD-A Pilot Study
- Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
- Does the liver facilitate aging-related cognitive impairment: Conversation between liver and brain during exercise?
- The fatty acid omega hydroxylase genes (CYP4 family) in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD): An RNA sequence database analysis and review
- COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS
- Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
- The association between diverse serum folate with MAFLD and liver fibrosis based on NHANES 2017-2020
- Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study
- Genetic and Lifestyle Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Relationship with Premature Coronary Artery Disease: A Study on the Pars Cohort
- An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease
- Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies
- The Effects of Synbiotics on the Liver Steatosis, Inflammation, and Gut Microbiome of Metabolic Dysfunction-associated Liver Disease Patients-Randomized trial
- Adding a Leafy Vegetable Fraction to Diets Decreases the Risk of Red Meat Mortality in MASLD Subjects: Results from the MICOL Cohort
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
- Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
- Fish oil supplementation during pregnancy decreases liver endocannabinoid system and lipogenic markers in newborn rats exposed to maternal high-fat diet
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
Evidence Blueprint
From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
🌐 365 Days
VR Related Evidence Matrix
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Liver Disease (MASLD): Another matter to face through a holistic approach
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Liver Disease (MASLD): Another matter to face through a holistic approach
- Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease
- Metabolic disease and the liver: A review
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease
- MELD-Na score may underestimate disease severity and risk of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
- Influence of Gut Microbiota and Its Metabolites on Progression of Metabolism-Associated Fatty Liver Disease
- Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance
- Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- The Prothrombotic Tendency of Metabolic-Associated Fatty Liver Disease
- Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study
- Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease
- Metabolic dysfunction-associated fatty liver disease in people living with HIV
- Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
- Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD)
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
- Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity
- Spatial genomics: mapping human steatotic liver disease
- Potential Mechanisms Involving in the Pathogenesis of MASLD and Targets for Pharmacotherapy. Advancements in Metabolic Associated Steatotic Liver Disease (MASLD) Research: Diagnostics, Small Molecule Developments and Future Directions
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- MBOAT7 in liver and extrahepatic diseases
- Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation
- An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective
- Fatty liver disease's renaming impacts on drug clinical trials
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Review and expert opinion on MAFLD, oxidative stress and multifunctional management
- Metabolic dysfunction: The silenced connection with fatty liver disease
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
- Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic
- Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
- The Global Epidemic of Metabolic Fatty Liver Disease